Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,920,038
  • Shares Outstanding, K 96,630
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -535 M
  • EBITDA $ -504 M
  • 60-Month Beta 0.16
  • Price/Sales 2.93
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 66.48% (-52.50%)
  • Historical Volatility 57.66%
  • IV Percentile 55%
  • IV Rank 19.28%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 26) 2.35 (11.85%)
  • Put/Call Vol Ratio 7.17
  • Today's Volume 188
  • Volume Avg (30-Day) 425
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 22,163
  • Open Int (30-Day) 19,824
  • Expected Range 17.52 to 22.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.50
  • Number of Estimates 9
  • High Estimate -1.06
  • Low Estimate -2.01
  • Prior Year -1.57
  • Growth Rate Est. (year over year) +4.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.86 +0.05%
on 03/20/26
23.79 -16.48%
on 02/23/26
-2.85 (-12.54%)
since 02/20/26
3-Month
18.41 +7.93%
on 12/29/25
35.12 -43.41%
on 12/22/25
-13.63 (-40.69%)
since 12/19/25
52-Week
18.41 +7.93%
on 12/29/25
42.37 -53.10%
on 07/09/25
-19.02 (-48.91%)
since 03/20/25

Most Recent Stories

More News
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 19.87 (-2.69%)
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

NEW ORLEANS , March 20, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 6, 2026  to file lead plaintiff applications...

RARE : 19.87 (-2.69%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 19.87 (-2.69%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

NEW YORK , March 19, 2026 /PRNewswire/ --

RARE : 19.87 (-2.69%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE)....

RARE : 19.87 (-2.69%)
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law

SAN DIEGO , March 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August...

RARE : 19.87 (-2.69%)
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION

Know Your Rights: How Basic Inc. v. Levinson Enables Investor Recovery

RARE : 19.87 (-2.69%)
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

NEW YORK , March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

RARE : 19.87 (-2.69%)
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 19.87 (-2.69%)
DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO , March 13, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock...

RARE : 19.87 (-2.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 21.23
2nd Resistance Point 20.95
1st Resistance Point 20.41
Last Price 19.87
1st Support Level 19.59
2nd Support Level 19.32
3rd Support Level 18.78

See More

52-Week High 42.37
Fibonacci 61.8% 33.22
Fibonacci 50% 30.39
Fibonacci 38.2% 27.56
Last Price 19.87
52-Week Low 18.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.